No posters match these filters
iPeptides: An Extensible Python Toolkit for 3D Modeling, Enumeration and QSAR of Peptides25th EuroQSAR 2026
Discovery and Characterization of a Brain-Penetrant SHP2 InhibitorDDIP 2026
Mitigating Pyroglutamate in Microwave-Assisted SPPS: Side-Reaction Control and Sequence–Structure Influence19th Naples Workshop on Bioactive Peptides 2026
C3PO: Complex 3D Patient Organoids for Preclinical Drug Testing in Brain TumorsPRIM-TECH3R & BaCell 2026
A Functional Human iPSC-Derived Blood–Brain Barrier Model to Predict CNS Drug PenetrationPRIM-TECH3R
Putting DMPK Where It Matters Most: Enabling Exposure-Driven Lead SelectionDiscovery & Development Europe 2026
Discovery and In Vitro Characterization of Novel Coronavirus NSP13 Helicase InhibitorsDiscovery & Development Europe 2026
Focused Multiparameter Optimization to Convert Potent Allosteric SHP2 Inhibitors into Brain-Penetrant CandidatesNMCS 2026
One-Pot Solution-Phase Strategy for the Synthesis of Bicyclic Peptides Using the T3P/[Pd(PPh₃)₄] SystemTIDES 2026
Phenotypic-Based Discovery of Zika Virus Protease Inhibitors with Potent Cellular and In Vivo ActivityICAR 2026
Novel Small-Molecule Inhibitors of Coronavirus Discontinuous Transcription Identified through Integrated Screening ApproachesICAR 2026
C3PO: Complex 3D Patient Organoids for Preclinical Drug Testing in Brain TumorsAACR 2026
Electrophile-First Approach Enables Rapid Identification of ATP-Competitive Inhibitors of Werner HelicaseDrug Discovery Chemistry 2026
Establishment of an NMR Workflow to Identify and Validate MutSβ and/or MutSβ-DNA Binding InhibitorsCHDI Annual Conference 2026
Phenotypic Screen to Identify Inhibitors of Coronavirus Discontinuous TranscriptionSLAS 2026
Identification of Covalent Inhibitors Targeting NSP13 via Integrated Biochemical and Chemoproteomics ApproachesSLAS 2026
High-Throughput Automated Screening for Robust Peptide Bioanalysis and Protein Binding EvaluationEuropean Bioanalysis Forum Open Symposium (EBF) 2025
Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) Platform to Support Preclinical Studies in Peptide Radioligand TherapyTIDES Europe 2025
Phenotypic Screen to Identify Inhibitors of Coronavirus Discontinuous TranscriptionDrug Discovery ELRIG 2025
Identification of Hit Inhibitors of SARS-CoV-2 NSP13 Helicase through Comprehensive Screening CascadeDrug Discovery ELRIG 2025
Integrated Platforms for Rapid Identification of PROTACs and Covalent FragmentsXXIX National Meeting on Med Chem 2025
R2R01: A Potent Long-Acting RXFP1 Peptide Agonist in Phase 2 Development for Cardiovascular and Renal DisordersBoulder Peptide Symposium 2025
From Chimeric Fragments to Functional Degraders: A Streamlined Platform for PROTAC DiscoveryEFMC 2025
Identification of SARS-CoV-2 Helicase Inhibitors Part 2EFMC 2025
Identification of SARS-CoV-2 Helicase Inhibitors Part 1EFMC 2025
One-Pot Solution-Phase Strategy for the Synthesis of Bicyclic Peptides Using the T3P/[Pd(PPh₃)₄] SystemEPSC 2025
Generation and Biophysical Characterization of New α-Nsp13 Helicase mAbs, as a Powerful Tool for Studying SARS-CoV-2 Replication and Therapeutic TargetingEBSA 2025
C3PO: Complex 3D Patient Organoids for Preclinical Compound Testing in Brain TumorsBaCell 3D 2025
A Platform for Comprehensive CRISPR/Cas9 Genome Editing in Preclinical Research and Drug DiscoverySIBBM Frontiers in Molecular Biology 2025
Identification and Biophysical Assessment of mAb AM E3, an Innovative α-TLSPR ADC Candidate Aimed at Treating TLSPR/CRLF2-Rearranged Ph-like B-ALLAntibody Engineering & Therapeutics Europe 2025
Sequence-Driven Strategies for Optimizing ADME Properties of Therapeutic PeptidesTIDES 2025
AM E3-SG3249, a First-in-Class α-CRLF2 Antibody-Drug Conjugate for the Treatment of CRLF2-Rearranged Ph-like B-ALLAACR 2025
Advancing Treatment for Brain Tumors and Metastases with I-1000233, a Brain Permeable SHP2 InhibitorAACR 2025
Establishment of a Stable Cell Line Containing a Tet-Off Regulated Episomal DNA Vector Expressing a SARS-CoV-2 RepliconEuropean Congress of Virology 2025
High-Throughput Phenotypic Screening for the Development of Inhibitors Targeting Discontinuous Transcription in CoronavirusesEuropean Congress of Virology 2025
Enabling Rapid Hit Identification: Integrated Platforms for PROTACs and Covalent FragmentsDrug Discovery Chemistry 2025
High-Throughput Phenotypic Screening for the Development of Inhibitors Targeting Discontinuous Transcription in CoronavirusesICAR 2025
Discovery of New Covalent Werner Helicase Inhibitors by High Throughput Screening ApproachSLAS 2025
Discovery of I-1000233 and I-0436650, Two Potent, Selective SHP2 Allosteric InhibitorsSLAS 2025
Covalent Inhibitors: How We Can Find Them in an Early Stage of a Drug Discovery ProgramSLAS 2024
Development of Biochemical and Biophysical Assays for the Identification of Peptides Targeting the MLH1-MSH3 Protein-Protein InteractionDrug Discovery
Compound Collection ManagementEFMC-ISMC
Design of a PROTAC Toolkit for the Identification of New Hits by Direct to Biology (D2B) ApproachEFMC-YMCS
Covalent Fragment-Based Drug Discovery Platform at IRBMEFMC-YMCS
SPR Technology for the Identification of New Therapeutic Agents from Phage Display LibrariesDIPIA
Discovery of I-1000233, a Potent, Selective, and Brain Permeable SHP2 Allosteric InhibitorSIC
Development of a New Bioanalytical Method for Selective Measurement of Wild-Type Huntingtin in Human Cerebrospinal FluidEHDN & Enroll-HD
Insights into the DNA Mismatch Repair System Exploiting a Frameshift Mutator Cell-Based Assay to Identify New Targets and Potential Treatments for Huntington’s DiseaseEHDN & Enroll-HD